HUM
HUMANA INC
NYSE: HUM · Louisville, KY · Healthcare
$363.18+7.20 (+2.02%)Closed
Market Cap$43.57B
Cash$9.53Bmost recent
Runwayprofitable
P/E (TTM)36.9EPS $9.84
52-Wk Range$162.84 – $363.18
Avg Volume1.8M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$363.18+6.9%
Pipeline

Drug candidates sponsored by HUMANA · ClinicalTrials.gov

29 drugs · 29 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 1Growth Hormone
Infertility
Completed
2016-12past
1
N/AUnnamed
Obesity+6 more
Completed
2003-07-01past
1
N/AUnnamed
Atopic Dermatitis
Completed
2012-11past
1
N/AUnnamed
Posture Disorders in Children
Completed
2013-05past
1
N/AUnnamed
Infertility
Completed
2013-06past
1
N/AUnnamed
Intellectual Disability
Completed
2015-07past
1
N/AUnnamed
Subfertility
Withdrawn
2016-01past
1
N/AUnnamed
Resistance Training
Completed
2017-10-28past
1
N/AUnnamed
Female Infertility
Terminated
2018-01past
1
N/AUnnamed
Psychomotor Status+2 more
Completed
2019-12past
1
N/AUnnamed
Edema Leg
Completed
2020-06-30past
1
N/AUnnamed
Obesity
Completed
2020-10past
1
N/AUnnamed
Facemask Impact on Cardiorespiratory Performance
Completed
2021-01-30past
1
N/AUnnamed
Healthy Males+1 more
Unknown
2021-04-12past
1
N/AHormonal Therapy Agent
Non-obstructive Azoospermia+3 more
Completed
2021-09-15past
1
N/AUnnamed
Diabetes Mellitus, Type 2+1 more
Unknown
2021-11-30past
1
N/AUnnamed
Sodium Bicarbonate
Completed
2022-04-27past
1
N/AUnnamed
Training+3 more
Completed
2022-12-30past
1
N/AUnnamed
Polycystic Ovary Syndrome+2 more
Unknown
2023-06-30past
1
N/AUnnamed
Green Exercise+1 more
Completed
2023-11-30past
1
N/AUnnamed
Normobaric Hypoxia+2 more
Unknown
2024-04past
1
N/AUnnamed
Normobaric Hypoxia+2 more
Unknown
2024-04past
1
N/AUnnamed
Fatigue Syndrome, Chronic
Unknown
2024-05past
1
N/AUnnamed
Diabetes Mellitus, Type 2
Unknown
2024-07past
1
N/AUnnamed
Dehydration+1 more
Unknown
2024-10-31past
1
N/AUnnamed
Pre-diabetes
Recruiting
2026-07-30
1
N/AUnnamed
Breast Cancer-Related Lymphedema
Not yet recruiting
2027-12
1
N/AUnnamed
Coronary Arterial Disease (CAD)
Not yet recruiting
2027-12-01
1
N/AUnnamed
Menstrual Cycle+2 more
Recruiting
2027-12-01
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for HUM. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.